Bifid Uvula

Breakthroughs in Atopic Dermatitis with Linda Stein Gold, MD: Primary Viewpoints Podcast

Improvement in AD signs and symptoms continued through 56 weeks of treatment with the PDE4 inhibitor including when used just twice weekly as prophylaxis.

Linda Stein Gold, MD;Sydney Jennings

March 9th 2025

Upadacitinib Demonstrates Superior Regional, Overall Efficacy vs Dupilumab in Atopic Dermatitis: Level Up Phase 3b/4 Trial Findings

“I think it’s important to have a lot of tools in our toolbox, and [tapinarof cream 1%] is one that gives us great flexibility," said Linda Stein Gold, MD.

Primary Viewpoints: Immunizations with Dr Steven P. Furr

Dupilumab-treated participants with recalcitrant head and neck symptoms who were switched to upadacitinib rapidly reached EASI 75 and steadily improved, among other findings.

Keith A. Reynolds

October 1st 2024

FDA Submission Planned for Nonopioid Cebranopadol Following Positive Phase 3 Results: Tris Pharma Update

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Steven P. Furr, former president of the American Academy of Family Physicians.

Cardiovascular Health Maintained Over Time Linked to Reduced Risk of Neurodegenerative Disease, Study Suggests

Positive findings for postsurgical acute pain relief from the pivotal phase 3 ALLEVIATE-2 trial complete the development program, allowing plans for NDA submission.

Atopic Dermatitis Update: Roflumilast 0.15% Cream Shows Long-Term Safety and Efficacy Plus Benefit with Proactive Use

Higher levels of cardiovascular health were associated with lower levels of neurofilament light chain across age, sex, race/ethnicity, and Alzheimer disease risk.

Related Content

Breakthroughs in Atopic Dermatitis with Linda Stein Gold, MD: Primary Viewpoints Podcast

Improvement in AD signs and symptoms continued through 56 weeks of treatment with the PDE4 inhibitor including when used just twice weekly as prophylaxis.

Linda Stein Gold, MD;Sydney Jennings

March 9th 2025

Upadacitinib Demonstrates Superior Regional, Overall Efficacy vs Dupilumab in Atopic Dermatitis: Level Up Phase 3b/4 Trial Findings

“I think it’s important to have a lot of tools in our toolbox, and [tapinarof cream 1%] is one that gives us great flexibility," said Linda Stein Gold, MD.

Primary Viewpoints: Immunizations with Dr Steven P. Furr

Dupilumab-treated participants with recalcitrant head and neck symptoms who were switched to upadacitinib rapidly reached EASI 75 and steadily improved, among other findings.

Keith A. Reynolds

October 1st 2024

FDA Submission Planned for Nonopioid Cebranopadol Following Positive Phase 3 Results: Tris Pharma Update

"Primary Viewpoints," a podcast from Patient Care Online, brings you an exclusive interview with Steven P. Furr, former president of the American Academy of Family Physicians.

Cardiovascular Health Maintained Over Time Linked to Reduced Risk of Neurodegenerative Disease, Study Suggests

Positive findings for postsurgical acute pain relief from the pivotal phase 3 ALLEVIATE-2 trial complete the development program, allowing plans for NDA submission.